Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Neoplasms 78%
3. Lung Neoplasms 54%
4. Pemetrexed 52%
5. gemcitabine 37%
6. Pharmacokinetics 34%
7. Maximum Tolerated Dose 33%
8. Small Cell Lung Carcinoma 32%
9. Drug Therapy 32%
10. Therapeutics 32%
11. Farnesyltranstransferase 29%
12. Survival 27%
13. Sorafenib 26%
14. Carboplatin 26%
15. Clinical Trials 24%
16. Cisplatin 22%
17. Mesothelioma 19%
18. tipifarnib 19%
19. Irinotecan 17%
20. Mitogen-Activated Protein Kinase Kinases 16%
21. Bortezomib 16%
22. Progression-Free Survival 15%
23. NSC 366140 15%
24. ErbB Receptors 15%
25. Paclitaxel 15%
26. Breast Neoplasms 14%
27. Biomarkers 13%
28. Docetaxel 13%
29. Mutation 13%
30. Appointments and Schedules 12%
31. Apoptosis 12%
32. Antineoplastic Agents 12%
33. Radiotherapy 12%
34. Safety 12%
35. lonafarnib 12%
36. Malignant Mesothelioma 12%
37. Transferases 11%
38. Pancreatic Neoplasms 11%
39. Protein-Tyrosine Kinases 11%
40. Bevacizumab 11%
41. Thorax 11%
42. Proteins 11%
43. Platinum 11%
44. Pharmaceutical Preparations 10%
45. National Cancer Institute (U.S.) 10%
46. Folic Acid Antagonists 10%
47. ras Proteins 10%
48. Topotecan 9%
49. Neutropenia 9%
50. Vascular Endothelial Growth Factor A 9%